The present invention relates to methods of reducing cardiotoxicity and/orimproving survival from treatment with anthracycline agents comprising administeringa therapeutically effective amount of a composition comprising a vasopressinantagonist compound or a pharmaceutically acceptable salt thereof as an activeingredient, administered simultaneously or prior to the anthracycline administration.